Harnessing a Novel E3 Ligase-Targeting DAC to Overcome Hematologic Toxicity in ADCs
- Engineering a degrader payload that recruits a novel E3 ligase to enable selective degradation of tumor-driving proteins with reduced hematologic offtarget effects
- Advancing beyond traditional cytotoxic payloads by leveraging targeted protein degradation to minimize collateral damage to healthy blood cell lineages
- Unlocking a new class of safer, next-gen DACs with differentiated biological mechanisms to improve therapeutic index across hematologic indications